Medicare Enrolled
Dr. Shehzad Topiwala, MD
Endocrinology · Stockbridge, GA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Topiwala from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Topiwala?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Topiwala
Dr. Shehzad Topiwala is an endocrinology specialist in Stockbridge, GA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Topiwala performed 1,867 Medicare services across 864 unique beneficiaries.
Between the years covered by Open Payments, Dr. Topiwala received a total of $37,392 from 61 pharmaceutical and/or device companies across 680 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Topiwala is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 33% volume in GA
$37,392 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,867
Medicare services
Top 33% in GA for endocrinology
864
Unique beneficiaries
$69
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~104 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
519 | $92 | $164 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
335 | $67 | $113 |
| Continuous glucose monitoring with interpretation This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results. |
161 | $26 | $100 |
| Ultrasound of head and neck soft tissue This procedure uses sound waves to create images of the soft tissues in the head and neck area. It allows for the visualization of structures beneath the skin without using radiation. |
121 | $79 | $171 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
115 | $37 | $77 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
114 | $38 | $89 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
112 | $103 | $250 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
97 | $49 | $63 |
| Remote vital sign monitoring management, each additional 20 minutes This code covers the time spent by a provider managing patient data from remote vital sign monitoring devices. It applies to each additional 20-minute increment beyond the initial monthly service period. |
61 | $31 | $63 |
| Chronic care management, additional 20 min/month This service covers an extra 20 minutes of clinical staff time directed by a healthcare professional for managing two or more chronic conditions each calendar month. |
59 | $37 | $50 |
| New patient office visit, complex (60-74 min) | 41 | $120 | $316 |
| Ultrasound-guided fine needle aspiration biopsy, first lesion A biopsy procedure where a thin needle is used to collect tissue samples from a growth, guided by ultrasound imaging. This code applies to the first lesion or mass sampled during the session. |
32 | $105 | $500 |
| Continuous glucose monitoring, sensor under skin This procedure involves continuous monitoring of blood sugar levels in tissue fluid using a sensor placed under the skin with provider-supplied equipment. |
31 | $112 | $250 |
| Continuous glucose monitoring, tissue fluid This procedure involves continuous monitoring of blood sugar levels in tissue fluid using a sensor placed under the skin. |
30 | $44 | $80 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
24 | $89 | $221 |
| Remote physiologic monitoring setup and education Initial setup of remote monitoring equipment and patient education on its use. |
15 | $14 | $27 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$37,392
Total received (2018-2024)
Avg $5,342/year across 7 years
Top 11% in GA for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
61
Companies
680
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$21,635 (57.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,557 (41.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$200 (0.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,105
2023
$6,749
2022
$3,583
2021
$3,669
2020
$522
2019
$5,767
2018
$12,998
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$1,642
Xeris Pharmaceuticals, Inc.
$510
Radius Health, Inc.
$291
Novo Nordisk Inc
$282
Bayer Healthcare Pharmaceuticals Inc.
$266
Amgen Inc.
$254
Dexcom, Inc.
$141
Insulet Corporation
$79
Mannkind Corporation
$66
Amphastar Pharmaceuticals, Inc.
$64
CeQur Corporation
$57
Abbott Laboratories
$56
RECORDATI_RARE_DISEASES_INC.
$53
Amneal Pharmaceuticals LLC
$52
Esperion Therapeutics, Inc.
$36
Novartis Pharmaceuticals Corporation
$35
Ascendis Pharma Inc
$34
Boehringer Ingelheim Pharmaceuticals, Inc.
$32
ABBVIE INC.
$31
Tandem Diabetes Care, Inc.
$29
Astellas Pharma US Inc
$22
Medtronic, Inc.
$22
SANOFI-AVENTIS U.S. LLC
$20
Antares Pharma, Inc.
$16
IBSA Pharma Inc.
$16
Top 3 companies account for 59.5% of 2024 payments
All-time payments by company (2018-2024) ›
SANOFI-AVENTIS U.S. LLC
$14,662
Xeris Pharmaceuticals, Inc.
$4,160
Lilly USA, LLC
$2,806
Novo Nordisk Inc
$2,621
Medtronic MiniMed, Inc.
$1,661
Amgen Inc.
$1,621
Medtronic, Inc.
$1,200
Bayer Healthcare Pharmaceuticals Inc.
$558
Dexcom, Inc.
$487
Boehringer Ingelheim Pharmaceuticals, Inc.
$466
Esperion Therapeutics, Inc.
$397
Bayer HealthCare Pharmaceuticals Inc.
$382
Insulet Corporation
$378
Amneal Pharmaceuticals LLC
$356
Radius Health, Inc.
$339
Horizon Therapeutics plc
$313
Amarin Pharma Inc.
$302
AstraZeneca Pharmaceuticals LP
$288
Abbott Laboratories
$288
Vertex Pharmaceuticals Incorporated
$257
Tandem Diabetes Care, Inc.
$254
Antares Pharma, Inc.
$251
TerSera Therapeutics LLC
$233
Merck Sharp & Dohme Corporation
$228
Radiometer America, Inc
$221
Corcept Therapeutics
$219
AbbVie, Inc.
$215
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$206
GENZYME CORPORATION
$200
CeQur Corporation
$187
VERTEX PHARMACEUTICALS INCORPORATED
$171
RECORDATI_RARE_DISEASES_INC.
$157
AbbVie Inc.
$105
EISAI INC.
$104
Mannkind Corporation
$93
Shire North American Group Inc
$92
Ascendis Pharma Inc
$91
Zealand Pharma US, Inc.
$72
Amphastar Pharmaceuticals, Inc.
$64
GRT US Holding, Inc.
$54
Novartis Pharmaceuticals Corporation
$54
Nevro Corp.
$54
Senseonics, Incorporated
$52
ABBVIE INC.
$50
Ipsen Biopharmaceuticals, Inc
$50
Ultragenyx Pharmaceutical Inc.
$38
IBSA Pharma Inc.
$35
Smith+Nephew, Inc.
$34
Rhythm Pharmaceuticals, Inc.
$33
DEXCOM, INC.
$24
Watermark Medical, Inc.
$24
Tolmar, Inc.
$24
Astellas Pharma US Inc
$22
Amryt Pharma Holdings Ltd
$22
Averitas Pharma Inc.
$21
Clarus Therapeutics Inc.
$21
Acerus Pharmaceuticals Corporation
$18
Allergan, Inc.
$15
Merck Sharp & Dohme LLC
$15
Alfasigma USA, Inc.
$13
Kowa Pharmaceuticals America, Inc.
$13
Top 3 companies account for 57.8% of all-time payments
Associated products mentioned in payments ›
AFREZZA · ARES HOME SLEEP TESTING DEVICE · BAQSIMI · CYCLOSET · CeQur Simplicity · Cryvista · DEXCOM G6 CGM SYSTEM · DEXCOM G6 TRANSMITTER · DEXCOM G7 GSS (161) · DISEASE STATE · Dexcom CGM · Dexcom G6 Transmitter · EVENITY · Eversense · FARXIGA · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · GVOKE HYPOPEN · GVOKE PFS · Guardian Sensor 3 · HUMULIN · Hb801 · INPEN SMART INSULIN DELIVERY SYSTEM · InPen · JANUVIA · JARDIANCE · JATENZO · JUXTAPID · Kerendia · Korlym · LEQVIO · LICART · LOKELMA · LYUMJEV · Lenvima · Livalo · MINIMED 770G · MINIMED 780G · MOUNJARO · Minimed 530G · Minimed 670G System · Minimed 770G System · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NEXLIZET · NOCDURNA · Natesto · Omnipod · Ozempic · Prolia · QUTENZA · Qutenza · RECORLEV · RYBELSUS · Repatha · Rybelsus · SIGNIFOR LAR · SKYTROFA · SOLIQUA · SOLIQUA 100/33 · SOMATULINE DEPOT · SOTAGLIFLOZIN · STEGLATRO · SYNTHROID · Santyl · Saxenda · Senza · Synthroid · TEFLARO · TEPEZZA · TOUJEO · TRULICITY · TZIELD · Tirosint · Tymlos · UNITHROID · Vascepa · Veozah · Wegovy · XYOSTED · Xultophy 100/3.6 · ZEGALOGUE · ZEPBOUND · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (58%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Endocrinologists within 10 mi
81
Per 100K population
33.0
County median income
$81,612
Nearest hospital
PIEDMONT HENRY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Topiwala is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 11% of GA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Topiwala experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Topiwala performed 519 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Topiwala receive payments from pharmaceutical companies?
Yes. Dr. Topiwala received a total of $37,392 from 61 companies across 680 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Topiwala's costs compare to other endocrinologists in Stockbridge?
Dr. Topiwala's average Medicare payment per service is $69. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Topiwala) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Endocrinology
Common procedures, typical costs, and what industry payments mean in endocrinology.
Same specialty & city
Endocrinologists in Stockbridge
Browse endocrinologists in Stockbridge ranked by procedure volume and transparency data.
Highest volume
Top Endocrinologists in GA
Endocrinologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Endocrinologists in GA
Which GA endocrinologists receive the most from drug and device companies.
By company
SANOFI-AVENTIS U.S. LLC Payments to Doctors
See all physicians who received payments from SANOFI-AVENTIS U.S. LLC.
By company
Xeris Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Xeris Pharmaceuticals, Inc.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology